ReviewFrontiers in immunology2026
Successful treatment of hidradenitis suppurativa with vunakizumab: a case report and literature review.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hidradenitis suppurativa (HS) is a chronic, recurrent, and disabling inflammatory skin disorder. To our knowledge, this study reports the first use of vunakizumab, a domestically developed anti-IL-17A monoclonal antibody, for the treatment of HS. We present the case of a 17-year-old boy with a 5-year history of recurrent painful nodules and abscesses on the buttocks who had been repeatedly misdiagnosed with common acute bacterial infections and had responded poorly to conventional antibiotics. After 8 weeks of treatment with vunakizumab, which offered a pharmacoeconomic advantage during the transition period before its inclusion in China's national insurance system, the patient showed marked improvement, with complete resolution of nodules, abscesses, and tunnels and no recurrence or significant adverse events during 10 months of follow-up. This case highlights the potential of vunakizumab in the treatment of HS and supports the pathogenic role of IL-17 in the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.